A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

This study is currently recruiting participants.
Verified April 2014 by UCB, Inc.
Sponsor:
Information provided by (Responsible Party):
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT00938431
First received: July 2, 2009
Last updated: April 14, 2014
Last verified: April 2014

July 2, 2009
April 14, 2014
October 2009
March 2015   (final data collection date for primary outcome measure)
Number of subjects that report at least one Treatment-emergent Adverse Event during the study (approximately 13 weeks) [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
Number of subjects that report at least one treatment-emergent adverse event [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00938431 on ClinicalTrials.gov Archive Site
  • Mean LCM plasma concentration at Visit 5 (Day 27/28) or Early Termination [ Time Frame: Visit 5 (Day 27/28) or Early Termination ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration at Visit 5 (Day 27/28) or Early Termination [ Time Frame: Visit 5 (Day 27/28) or Early Termination ] [ Designated as safety issue: No ]
  • Change in seizure frequency from Baseline to End of Treatment [ Time Frame: From Baseline to End of Treatment ] [ Designated as safety issue: No ]

    For assessment of the Clinical Global Impression of Change, the investigator should provide his/her assessment of the subject's clinical status, compared to Baseline (Visit 1), including an evaluation of seizure frequency and intensity, the occurrence of AEs, and subject's functional status.

    The investigator will be asked to check the number that best describes the subject's condition over the past 4 weeks compared to Baseline:

    1. Very much improved
    2. Much improved
    3. Minimally improved
    4. No Change
    5. Minimally worse
    6. Much worse
    7. Very much worse
  • Mean Caregiver Global Impression of Change score at Visit 5 (Day 27/28) or Early Termination [ Time Frame: Visit 5 (Day 27/28) or Early Termination ] [ Designated as safety issue: No ]

    For the assessment of the Caregiver Global Impression of Change, the caregiver (including parent/legal guardian) should provide his/her assessment of the subject's clinical status,compared to Baseline (Visit 1), including an evaluation of seizure frequency and intensity, the occurrence of AEs, and subject's functional status.

    The caregiver will be asked to check the number that best describes the subject's condition over the past 4 weeks compared to Baseline:

    1. Very much improved
    2. Much improved
    3. Minimally improved
    4. No change
    5. Minimally worse
    6. Much worse
    7. Very much worse
  • Mean in Clinical Global Impression of Change score at Visit 5 (Day 27/28) or Early Termination [ Time Frame: Visit 5 (Day 27/28) or Early Termination ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: Pre-dose (-1 to 0 hours) ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 18-42 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 48-72 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 90 to 150 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 210 to 270 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 6 to 9 hours post-dose ] [ Designated as safety issue: No ]
  • Mean LCM plasma concentration [ Time Frame: 11 to 12 hours post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: Pre-dose (-1 to 0 hours) ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 18-42 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 48-72 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 90 to 150 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 210 to 270 minutes post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 6 to 9 hours post-dose ] [ Designated as safety issue: No ]
  • Mean SPM 12809 plasma concentration [ Time Frame: 11 to 12 hours post-dose ] [ Designated as safety issue: No ]
  • Change in seizure frequency [ Time Frame: Baseline to Withdrawal/End of Treatment (Week 4, 5, or 6 depending on maximum recommended dose) ] [ Designated as safety issue: No ]
  • Change in Clinical Global Impression of Change score [ Time Frame: Early Termination Visit/End of Treatment (Week 4 for maximum dose of 8mg/kg/day, Week 5 for maximum dose of 10mg/kg/day or Week 6 for maximum dose of 12mg/kg/day) ] [ Designated as safety issue: No ]
  • Change in Caregiver Global Impression of Change [ Time Frame: Early Termination Visit/End of Treatment (Week 4 for maximum dose of 8mg/kg/day, Week 5 for maximum dose of 10mg/kg/day or Week 6 for maximum dose of 12mg/kg/day) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures
A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures

The purpose of this study is to evaluate the safety and pharmacokinetics of LCM syrup in children ages 1 month-17 years with uncontrolled partial seizures when added to 1 to 3 other antiepileptic drugs (AEDs) seizure medications.

Six subjects aged 5-11 will initially be enrolled at the 8 mg/kg/day dose level. Upon completion of the trial for these subjects, pharmacokinetic and safety data will be analyzed to determine the target dose for the remaining subjects (either 8, 10 or 12 mg/kg/day). Depending on the selected target dose, different age-based Cohorts of subjects will be enrolled. LCM will be increased 2 mg/kg/day per week until the target dose or maximum dose able to be tolerated is achieved.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Epilepsy
Drug: Lacosamide

Lacosamide oral solution (syrup) 8 mg/kg/day, 10 mg/kg/day, and/or 12 mg/kg/day.

Depending on the target dose, treatment duration can last up to 42 days.

Other Name: Vimpat®
  • Experimental: Lacosamide - Age 5 - 11 years (up to 8 mg/kg/day))
    Cohort 1 (Age 5 - 11 years)
    Intervention: Drug: Lacosamide
  • Experimental: Lacosamide - (Age 12 - 17 years)
    Cohort 2 (Age 12 - 17 years); 8 mg/kg/day, 10 mg/kg/day, or 12 mg/kg/day.
    Intervention: Drug: Lacosamide
  • Experimental: Lacosamide (Age 2 - 4 years)
    Cohort 3 (Age 2 - 4 years); 8 mg/kg/day, 10 mg/kg/day, or 12 mg/kg/day.
    Intervention: Drug: Lacosamide
  • Experimental: Lacosamide (Age 5 - 11 years)
    Cohort 4 (Age 5 - 11 years); 10 mg/kg/day or 12 mg/kg/day.
    Intervention: Drug: Lacosamide
  • Experimental: Lacosamide (Age 1 month - < 2 years)
    Cohort 5 ((Age 1 month - < 2 years); 8 mg/kg/day, 10 mg/kg/day, or 12 mg/kg/day
    Intervention: Drug: Lacosamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
42
March 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is male or female between 1 month and 17 years of age inclusive
  • Subject's Body Mass Index (BMI) is within the 5th to 95th percentile for his/her age group
  • Subject has a diagnosis of epilepsy with partial-onset seizures
  • Subject has been observed to have uncontrolled partial-onset seizures after an adequate course of treatment with at least 2 anti-epileptic drugs (AEDs) (concurrently or sequentially)
  • Subject has been observed to have at least 2 countable seizures in the 4-week period prior to Screening
  • Subject is on a stable dosage regimen of 1 to 3 AEDs

Exclusion Criteria:

  • Subject is currently participating or has participated within the last 2 months in any study of an investigational drug or experimental device
  • Subject with seizures that are uncountable due to clustering during the 8-week period prior to study entry
  • Subject is on a ketogenic or other specialized diet
  • Subject has a history of primary generalized epilepsy
  • Subject has a history of status epilepticus within the 6-month period prior to Screening
  • Subject is receiving concomitant treatment with felbamate or has received previous felbamate therapy within the last 6 months prior to Screening
  • Subject has taken or is currently taking vigabatrin
  • Subject is taking monoamine oxidase (MAO) inhibitors or narcotic analgesics
  • Subject has a lifetime history of suicide attempt, or has suicidal ideation in the past 6 months
Both
1 Month to 17 Years
No
Contact: UCB Clinical Trial Call Center +1 877 822 9493
United States,   Belgium,   Mexico
 
NCT00938431
SP847
No
UCB, Inc.
UCB, Inc.
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB, Inc.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP